Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Evaluating whether de-escalating to less toxic neoadjuvant chemotherapy yields equivalent outcomes would require an impractically large randomized trial because baseline cure rates are already extremely high. Following the APT trial's precedent, investigators designed the single-arm CompassHER2 trial powered to test if four cycles of THP achieve a three-year recurrence-free survival benchmark greater than 92%.

Related Insights

While ER-positive/HER2-positive breast cancer typically yields lower pCR rates (34% overall), the HER2-DX pCR score revealed an absolute 40% difference between low and high/medium scores. Patients with ER-positive tumors and high or medium scores achieved pCR rates of 58% to 61% with four cycles of THP, effectively identifying candidates who can safely forgo multi-agent chemotherapy despite traditionally lower response expectations.

For lower-risk Stage 2/3 HER2+ breast cancer, clinicians can start with THP, assess response via MRI, and only then proceed to TDXD if necessary. This risk-stratified approach to the DESTINY-Breast11 regimen can spare some patients the unique toxicities of TDXD.

The trial's active monitoring arm had a 96% overall survival rate at 3 years. This high baseline survival, due to effective subsequent treatments for relapsed patients, makes it statistically challenging to demonstrate an OS benefit for any adjuvant therapy. This highlights a growing challenge for adjuvant trial design in cancers with effective salvage options.

Despite new therapies, 16-19% of patients achieve very long progression-free survival on the standard THP regimen. These "exceptional responders" often present with de novo, non-visceral disease, suggesting they are a distinct subgroup that may not require immediate escalation to newer treatments.

Traditional non-inferiority trials for reducing treatment are difficult to fund and execute. A proposed paradigm shift is to use superiority trial designs, where the burden of proof is on demonstrating that a higher dose or longer duration of therapy is actually better than a de-escalated approach.

The DESTINY-Breast11 trial showed a neoadjuvant regimen of TDXD followed by THP achieved a 67.3% pathologic complete response (pCR) rate in high-risk HER2+ breast cancer. This is the highest pCR rate seen in a registrational trial, signaling a potential new standard of care.

The impressive 68% pathological complete response (pCR) in the SAKK neoadjuvant bladder cancer study may be misleading. Such high rates in single-arm trials are often driven by patient selection biases, such as enrolling patients with earlier T2 disease and those who've had thorough initial surgeries.

The DESTINY-Breast11 trial demonstrated superior pCR rates using neoadjuvant T-DXd followed by THP, but Dr. Nadine Tung cautions against treating all patients with maximally intensive therapy. Because two-thirds of ER-negative patients already achieve pCR with just four cycles of THP, universal escalation causes overtreatment. Instead, clinicians should reserve intensive antibody-drug conjugate regimens for patients with high tumor burden or unfavorable biology.

The SmartStop trial represents a paradigm shift by using a chemotherapy-free drug combination as an initial induction treatment. This "iconoclastic" design challenges the decades-old R-CHOP standard, using initial response to guide subsequent chemotherapy intensity. This approach could de-escalate treatment for strong responders, personalizing therapy and potentially reducing long-term toxicity.

Although clinical guidelines often recommend platinum-based TCHP, emerging evidence from trials like NEOCARP and Helena 06 shows that platinum-free THP yields comparable pathologic complete response rates. Dr. Nadine Tung explains that historically, platinum added minimal benefit over taxanes and dual-HER2 antibodies, making platinum omission an attractive de-escalation strategy for stage 2 patients to avoid unnecessary toxicities like neuropathy.